Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease

Rosa Malo de Molina, Marcos I. Restrepo, Eric M. Mortensen, Jose L. Izquierdo, Antonio Anzueto

Research output: Contribution to journalArticlepeer-review


Inhaled corticosteroids (ICS) have been recommended for use in patients with chronic obstructive pulmonary disease (COPD) in order to decrease exacerbation rates and improve health related quality of life parameters. Nevertheless, recent studies have reported an increased risk of pneumonia associated with this treatment. However, most studies were not specifically designed to detect pneumonia as a possible secondary effect and for this reason it is difficult to determine whether this risk exists and assess its magnitude. This paper reviews the published studies reporting pneumonia events in COPD patients treated with ICS.

Original languageEnglish (US)
Pages (from-to)162-166
Number of pages5
JournalCurrent Respiratory Medicine Reviews
Issue number3
StatePublished - 2010


  • Chronic obstructive pulmonary disease
  • Inhaled corticosteroids
  • Pneumonia

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

Cite this